Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670143 | 0.93 | MDM4 (0.48) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL24414112 | 0.87 | MMP9 (0.53) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL30595558 | 0.87 | MMP9 (0.53) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL25412232 | 0.87 | MMP9 (0.53) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL13323329 | 0.87 | CTSL (0.47) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL8355963 | 0.87 | CTSL (0.47) | CTSLCTSBCTSSCTSKMDM4 | |
| SCHEMBL13743302 | 0.86 | ATM (0.53) | MDM4TP53CASP3TNFALDH1A1 | |
| SCHEMBL2977877 | 0.86 | ATM (0.53) | MDM4TP53CASP3TNFALDH1A1 | |
| SCHEMBL12531899 | 0.86 | ATM (0.53) | MDM4TP53CASP3TNFALDH1A1 | |
| SCHEMBL29401932 | 0.86 | ATM (0.53) | MDM4TP53CASP3TNFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528834-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20220372069-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-4036103-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | Nissan Chemical Corporation (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401978-A | Method for producing peptide compound | 日产化学株式会社 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528834-B2 | Method for producing peptide compound | VIP, IAPP, NPPA | CTSL 139/4885CTSB 559/4885CTSS 780/4885 |
| US-20220372069-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | CTSL 325/4885CTSB 498/4885CTSS 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.